within Pharmacolibrary.Drugs.C_CardiovascularSystem.C08C_SelectiveCalciumChannelBlockersWithMainlyVascula.C08CA16_Clevidipine;

model Clevidipine
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 0.00014116666666666666,
    adminDuration = 600,
    adminMass = 4 / 1000000,
    adminCount = 1,
    Vd = 0.00017,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 8.999999999999999e-05,
    k12 = 5.133333333333333e-05,
    k21 = 5.133333333333333e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Clevidipine</td></tr><tr><td>ATC code:</td><td>C08CA16</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>4</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.17</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.121</td><td>L/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Clevidipine is an ultrashort-acting dihydropyridine calcium channel blocker used for the rapid reduction of blood pressure in cases of acute hypertension. It is administered intravenously and is approved for use in clinical settings such as perioperative hypertension and hypertensive emergencies.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult subjects following intravenous infusion.</p><h4>References</h4><ol><li><p>Ericsson, H, et al., &amp; Regårdh, CG (2001). Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients. <i>Chirality</i> 13(3) 130–134. DOI:<a href=\"https://doi.org/10.1002/1520-636X(2001)13:3&lt;130::AID-CHIR1009&gt;3.0.CO;2-2\">10.1002/1520-636X(2001)13:3&lt;130::AID-CHIR1009&gt;3.0.CO;2-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11270321/\">https://pubmed.ncbi.nlm.nih.gov/11270321</a></p></li><li><p>Zuleta-Alarcón, A, et al., &amp; Bergese, S (2014). [The role of clevidipine in hypertension management: clinical results]. <i>Revista espanola de anestesiologia y reanimacion</i> 61(10) 557–564. DOI:<a href=\"https://doi.org/10.1016/j.redar.2014.06.006\">10.1016/j.redar.2014.06.006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/25236947/\">https://pubmed.ncbi.nlm.nih.gov/25236947</a></p></li><li><p>Ericsson, H, et al., &amp; Regårdh, CG (1999). Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 27(5) 558–564. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/10220482/\">https://pubmed.ncbi.nlm.nih.gov/10220482</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C08CA16 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Clevidipine;
